Thursday, November 21, 2024 11/21/2024

Seattle-Lausanne Clinical Trials Unit

Award Number: UM1AI069481
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

The Seattle-Lausanne Clinical Trials Unit (CTU) has a common vision to live in a world without new HIV infections and free of AIDS-related morbidity and death. To this end, we are committed to accelerate progress over the next seven years to: 1) develop a globally effective HIV vaccine, a combination broad neutralizing antibody immunoprophylaxis regimen that can prevent HIV, and an improved vaccine regimen to prevent Mycobacterium tuberculosis infection; and 2) discover novel and improved therapies that can effectively treat all persons living with HIV, prevent HIV disease and its co-morbidities, and lead to sustained viral remission without the need for ongoing treatment. In this renewal application for NIAID funding in 2020-2027, our CTU proposes continued support of the scientific priorities of the HIV Vaccine Trials Network (HVTN) and the HIV Adult Therapeutic Network (ACTG), through our three existing and highly integrated Clinical Research Sites (CRSs): the Seattle Vaccine Trials Unit (HVTN site), the Lausanne Vaccine and Immunotherapy Center (HVTN site) and the University of Washington AIDS Clinical Trials Unit (ACTG site). Our CTU is operating in a productive and intense period of clinical research on behalf of the networks, and we anticipate a seamless transition from our current portfolio to the proposed new studies initiated in the next cycle. Our CTU leaders and co-investigators are valuable members of the networks’ leadership and scientific committees; they chair and participate in high profile first-in-human studies and bring innovative designs to gain insights into the mechanisms by which candidate vaccines and novel therapeutics achieve their desired responses. Furthermore, our CRSs will continue to enroll and follow target populations in clinical trials and contribute outstanding data to advance promising immune-based, antiviral, and other therapeutic strategies. To achieve our vision and address the networks’ priorities, in Aim 1 we will harness the collective, diverse expertise of three internationally recognized thought leaders in the HIV field to provide scientific leadership and innovation to the HVTN and ACTG. In parallel, our CTU will advance the research careers, leadership skills and opportunities for early-stage physician scientists to foster the next generation of network investigators. In Aim 2, our governance and administrative structure will provide a transparent process for decision-making and effective oversight of communication, resource allocation, pharmacy, clinical and regulatory operations, and quality management to enable a highly integrated, productive CTU. In partnership with the HVTN and ACTG, in Aim 3 our three CRSs will conduct phase 1-4 clinical trials with the CTU support necessary to ensure the highest quality standards. In Aim 4, we will continue to involve our community partners to ensure their input and support, and to optimize enrollment and engagement of relevant populations in our clinical research activities. Importantly, we have the necessary resource commitments from our three institutions as needed to carry out this agenda and will leverage specialized expertise in our rich environment to foster diversity and innovation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $840,279 )
2025	2025	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	20	11/7/2024	NON-COMPETING CONTINUATION	$840,279
														Subtotal = $840,279

Issue Date FY: 2024 ( Subtotal = $1,857,698 )
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	003	19	6/26/2024	NON-COMPETING CONTINUATION	$1,044,047
2024	2024	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	19	11/2/2023	NON-COMPETING CONTINUATION	$813,651
2024	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	17	6/13/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2024	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	17	11/27/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $1,857,698

Issue Date FY: 2023 ( Subtotal = $1,857,247 )
2023	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	006	18	6/1/2023	NON-COMPETING CONTINUATION	$1,008,177
2023	2023	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	18	11/17/2022	NON-COMPETING CONTINUATION	$849,070
2023	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	004	16	5/15/2023	NON-COMPETING CONTINUATION	-$10,347
2023	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	003	17	5/2/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$17,090
2023	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	008	16	6/21/2023	NON-COMPETING CONTINUATION	$10,347
2023	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	005	16	5/15/2023	NON-COMPETING CONTINUATION	-$6,743
2023	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	007	16	6/21/2023	NON-COMPETING CONTINUATION	$6,743
2023	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	16	5/2/2023	NON-COMPETING CONTINUATION	-$17,090
2023	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	14	11/10/2022	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $1,857,247

Issue Date FY: 2022 ( Subtotal = $1,612,650 )
2022	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	16	5/27/2022	NON-COMPETING CONTINUATION	$0
2022	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	16	11/22/2021	NON-COMPETING CONTINUATION	$386,073
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	005	17	8/23/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	004	17	8/19/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$134,717
2022	2022	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	003	16	8/19/2022	NON-COMPETING CONTINUATION	-$134,717
2022	2022	FRED HUTCHINSON CANCER CENTER	1100 FAIRVIEW AVE N	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	17	5/27/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1,226,577
														Subtotal = $1,612,650

Issue Date FY: 2021 ( Subtotal = $1,608,983 )
2021	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	15	11/20/2020	COMPETING CONTINUATION	$745,820
2021	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	15	2/24/2021	COMPETING CONTINUATION	$863,163
2021	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	005	15	8/10/2021	COMPETING CONTINUATION	$17,090
2021	2021	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	15	2/19/2021	COMPETING CONTINUATION	$0
2021	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	004	14	8/10/2021	NON-COMPETING CONTINUATION	-$17,090
2021	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	003	14	2/25/2021	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $1,608,983

Issue Date FY: 2020 ( Subtotal = $2,215,996 )
2020	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	14	6/16/2020	SUPPLEMENT FOR EXPANSION	$299,401
2020	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	14	11/21/2019	NON-COMPETING CONTINUATION	$958,298
2020	2020	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	14	5/26/2020	NON-COMPETING CONTINUATION	$958,297
														Subtotal = $2,215,996

Issue Date FY: 2019 ( Subtotal = $2,302,202 )
2019	2019	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	13	11/15/2018	NON-COMPETING CONTINUATION	$1,151,102
2019	2019	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	13	5/17/2019	NON-COMPETING CONTINUATION	$1,151,100
														Subtotal = $2,302,202

Issue Date FY: 2018 ( Subtotal = $1,310,445 )
2018	2018	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	12	2/23/2018	NON-COMPETING CONTINUATION	$218,408
2018	2018	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	12	11/17/2017	NON-COMPETING CONTINUATION	$436,815
2018	2018	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	002	12	5/10/2018	NON-COMPETING CONTINUATION	$655,222
														Subtotal = $1,310,445

Issue Date FY: 2017 ( Subtotal = $1,284,773 )
2017	2017	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE N J6-300	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	11	11/18/2016	NON-COMPETING CONTINUATION	$1,284,773
														Subtotal = $1,284,773

Issue Date FY: 2016 ( Subtotal = $1,310,443 )
2016	2016	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE NO J6-330	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	10	11/5/2015	NON-COMPETING CONTINUATION	$1,310,443
														Subtotal = $1,310,443

Issue Date FY: 2015 ( Subtotal = $1,476,996 )
2015	2015	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE NO J6-330	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	001	9	6/30/2015	NON-COMPETING CONTINUATION	$200,000
2015	2015	FRED HUTCHINSON CANCER RESEARCH CENTER	1100 FAIRVIEW AVE NO J6-330	SEATTLE	WA	98109	KING	USA	Allergy and Infectious Diseases Research	000	9	11/18/2014	NON-COMPETING CONTINUATION	$1,276,996
														Subtotal = $1,476,996

Issue Date FY: 2014 ( Subtotal = $2,039,318 ) (Continued on the next page)
Grand Total All Awards = $20,861,062

Page 1 of 2 (60 items)12

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Seattle-Lausanne Clinical Trials Unit

Award Number: UM1AI069481

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer